David Greenberg, MD
Infectious Disease · Dallas, TXNPI 1477871184
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Shionogi Inc accounts for 63.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $5,818, more than ten times the $377 reported in 2019. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $566.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$11K
- Sarepta Therapeutics, Inc.$4K
- Janssen Research & Development, LLC$3K
- Paratek Pharmaceuticals, Inc.$114
- Biomerieux Inc$100
- Merck$91
- plus $161 from 3 others
Across 20 payments — averaging $57,249 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$966K
- Shionogi Inc$129K
- Depuy Synthes Products, Inc.$50K
What the payments were for
- Consulting fees$10,08056%
- Speaking & faculty fees$5,28729%
- Travel & lodging$2181%
- Food & beverage$2,53714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 17 | $11,457 |
| Sarepta Therapeutics, Inc. | 2 | $3,550 |
| Janssen Research & Development, LLC | 3 | $2,650 |
| Paratek Pharmaceuticals, Inc. | 4 | $114 |
| Biomerieux Inc | 1 | $100 |
| Merck | 1 | $91 |
| Nabriva Therapeutics, PLC | 1 | $70 |
| Melinta Therapeutics, LLC | 2 | $47 |
| Regeneron | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fetroja$5,860
How this compares
$18,122 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Dallas
- Elizabeth RaceDallas$1.5M
- Uriel SandkovskyDallas$320K
- Roger BedimoDallas$269K
- Edward DominguezDallas$121K
- Robert HardyDallas$116K
- Mezgebe BerheDallas$66K
- Ank NijhawanDallas$39K
- Philip KeiserDallas$38K
- Helen KingDallas$37K
- Jason GillmanDallas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.